ライフサイエンスコーパス: omeprazole

1 iod of heartburn-free days (23 vs 12 days on omeprazole).

2 en PHOPDT plus omeprazole compared with only omeprazole.

3 n FVB/N mice rendered hypergastrinemic using omeprazole.

4 increased (from 55% to 97%, P = 0.03) after omeprazole.

5 rchlorhydria) and control of all symptoms by omeprazole.

6 0, prevented inhibition of acid transport by omeprazole.

7 in PBMCs when compared with lansoprazole and omeprazole.

8 nificant difference between lansoprazole and omeprazole.

9 te, 36% would add antacid, and 13% would add omeprazole.

10 ridyl methylsulfinyl benzimidazoles, such as omeprazole.

11 SPEM or after decrease of stomach acid with omeprazole.

12 cleavage of progastrin at Lys residues after omeprazole.

13 -92 were not influenced by pretreatment with omeprazole.

14 laparoscopic Nissen fundoplication (LNF) vs. omeprazole.

15 t determine the specificity of P450 2C19 for omeprazole.

16 a drug interaction that was attributable to omeprazole.

17 ith or without inhibition of gastric acid by omeprazole.

18 ng the proton pump inhibitors (PPIs) such as omeprazole.

19 l to examine the effects of long-term use of omeprazole.

20 ncentrations in melanocytes was inhibited by omeprazole.

21 tion in upper gastrointestinal bleeding with omeprazole.

22 an drug substrate, the proton pump inhibitor omeprazole.

23 or lansoprazole rather than esomeprazole or omeprazole.

24 trial when clopidogrel was coprescribed with omeprazole.

25 n by the coadministration of esomeprazole or omeprazole.

26 ents when clopidogrel was co-prescribed with omeprazole.

27 ough the risk of diarrhea was increased with omeprazole.

28 en with an SIL-IS through a case study using omeprazole.

29 lansoprazole (25 microg/mL); c) control plus omeprazole (0.35 microg/mL); and d) control plus ranitid

30 with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to

31 ole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-

32 4 +/- 1.8 vs 2.1 +/- 2.2 hours, P = 0.0001), omeprazole (1.1 +/- 1.1 vs 4.4 +/- 1.3 hours, P < 0.0001

33 hetic CSF) was added to VCP in group II, and omeprazole (10(-5) mol/l of synthetic CSF) was added to

34 sus active comparator (amoxicillin, 3 g, and omeprazole, 120 mg), given as 4 capsules every 8 hours f

35 RHB-105 (amoxicillin, 3 g; omeprazole, 120 mg; and rifabutin, 150 mg) versus active

36 38.4 +/-94.2; lansoprazole 14.6+/-84.4; and omeprazole 15.1+/-48.9.

37 -2-pyridyl)methylsulfinyl]-1H-benzimidazole (omeprazole), 2-[(4-trifluoroethoxy-3-methyl-2-pyridyl)me

38 D were randomly allocated to either group 1 (omeprazole 20 mg + domperidone 30 mg) or group 2 (omepra

39 All patients received omeprazole 20 mg once daily for 3 weeks until endoscopy,

40 initial full-dose therapy, which usually is omeprazole 20 mg once daily, the aim is to use the lowes

41 intravenous infusion 8 mg/h for 3 days, then omeprazole 20 mg twice a day for 28 days).

42 lofenac slow-release 75 mg twice a day (with omeprazole 20 mg twice a day for gastroprotection) for a

43 azole 20 mg + domperidone 30 mg) or group 2 (omeprazole 20 mg) in an equal ratio; 2 capsules daily in

44 285 patients were randomly assigned omeprazole 20 mg, amoxycillin 1000 mg, and clarithromyci

45 nts were randomly assigned active treatment (omeprazole 20 mg, clarithromycin 250 mg, and tinidazole

46 he NSAID diclofenac (75 mg twice daily) plus omeprazole (20 mg once daily), and either rifaximin-EIR

47 ly), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily).

48 ly), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily); or (3) azithromycin (500

49 ial compared Gaviscon(R) (4 x 10 mL/day) and omeprazole (20 mg/day) in patients with 2-6 day heartbur

50 an alginate (Gaviscon(R), 4 x 10 mL/day) and omeprazole (20 mg/day) on GERD symptoms in general pract

51 pH monitoring after 7 days of treatment with omeprazole, 20 mg twice daily, followed by different tre

52 supplements at bedtime: placebo; additional omeprazole, 20 mg; ranitidine, 150 mg; and ranitidine, 3

53 l, which consisted of 100 mg caffeine, 20 mg omeprazole, 25 mg losartan, 30 mg dextromethorphan, and

54 Patients were randomized to 20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole

55 atients were randomized to either placebo or omeprazole (40 mg AM and 20 mg PM) groups for 7 days.

56 ve 3 and 4 were higher with rabeprazole than omeprazole (46 [37-55] vs. 30 [15-55] %, 9 [5-11] % for

57 160-383 (SRS-2-SRS-5) of P450 2C19 conferred omeprazole 5-hydroxylase activity to P450 2C9.

58 residues 160-227 of P450 2C19 also exhibited omeprazole 5-hydroxylase activity which was dramatically

59 A single mutation Ile99 --> His increased omeprazole 5-hydroxylase to approximately 51% of that of

60 0 2C9 to an enzyme with a turnover number of omeprazole 5-hyrdroxylation, which resembled that of P45

61 he alternative PPIs (8/52 pantoprazole, 6/52 omeprazole, 5/52 esomeprazole, 3/52 rabeprazole).

62 r presence of the H(+),K(+)-ATPase inhibitor omeprazole (60 mg kg(-1) I.P.), indomethacin blocked sim

63 elevated 5-6-fold by oral administration of omeprazole (75 mg/kg).

64 teraction and demonstrate assay sensitivity, omeprazole 80 mg) was given daily for 9 days.

65 germ-free mice that were either treated with omeprazole, a proton-pump inhibitor that suppresses acid

66 Omeprazole abolished RX 77368-induced acid secretion but

67 Pantoprazole and omeprazole accounted for 62% and 9% of concurrent PPI us

68 ial acid and nonacid reflux before and after omeprazole administration.

69 peridone combination was more effective than omeprazole alone in providing complete cupping of reflux

70 In addition, mice were treated with omeprazole alone or in combination with either YF476 or

71 Omeprazole also elevated VMAT2 expression in rats fasted

72 Omeprazole, an intravenous proton pump inhibitor, signif

73 ndomly to groups given hybrid therapy (40 mg omeprazole and 1 g amoxicillin, twice daily for 14 days;

74 testinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard rat

75 ascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omep

76 e to aryl hydrocarbon receptor (AhR) agonist omeprazole and a 10-fold induction in response to PXR ag

77 acid secretion is approximately 28 hours for omeprazole and approximately 46 hours for pantoprazole.

78 ostatic and hydrophobic interactions between omeprazole and DPPC rearranged the conformational state

79 ucing a set of 479 core genes common between omeprazole and esomeprazole treatments.

80 human esophageal cells to IL-13 and the PPIs omeprazole and esomeprazole were assessed by RT-PCR and

81 We found that omeprazole and its closely related congeners inhibited m

82 In doing so, we find omeprazole and maropitant are administered to a large pr

83 our work reveals probable overprescribing of omeprazole and maropitant citrate in hospitalised dogs,

84 To investigate the use of omeprazole and maropitant in our veterinary specialist h

85 age was blocked by the proton pump inhibitor omeprazole and mediated by the acid-activated protease p

86 and the patient was treated with intravenous omeprazole and oral antacid suspension.

87 Omeprazole and pantoprazole have no activity.

88 gnificantly lower with rabeprazole than with omeprazole and placebo (22 [14-53] vs. 54 [19-130] and 9

89 single oral dose of 20 mg rabeprazole, 20 mg omeprazole and placebo in obese subjects.

90 e (amoxicillin and sertraline) and positive (omeprazole and ranitidine) control exposures.

91 Omeprazole and SCH 28080 decreased IL-4-stimulated eotax

92 We investigated the effects of omeprazole and Sch 28080, a more specific and a more pot

93 o inhibitors of the apical H(+)/K(+) ATPase (omeprazole and SCH28080), thereby unmasking a stable, lo

94 The combination of omeprazole and verapamil suppressed IL-4-stimulated eota

95 amazepine, Dexamethasone, Phenobarbital, and Omeprazole) and at baseline (no treatment).

96 ith a proton-pump inhibitor (lansoprazole or omeprazole) and bismuth subsalicylate.

97 r lansoprazole, 1.43 (95% CI, 1.35-1.51) for omeprazole, and 2.33 (95% CI, 1.30-4.18) for pantoprazol

98 ns for 5 consecutive days concomitantly with omeprazole, and 4 weeks later during cycle 2 patients re

99 line Beecham, Philadelphia, PA), the antacid omeprazole, and dexamethasone was most effective in amel

100 dical therapies with somatostatin analogues, omeprazole, and locoregional tumor ablation have made a

101 al ambulatory pH monitoring with response to omeprazole, and provides additional insights into the pa

102 Atorvastatin, omeprazole, and several other drugs have been shown in p

103 alsartan/negative exposures; ROR : valsartan/omeprazole; and ROR : valsartan/ranitidine) showed the h

104 ior ulcer disease; antimicrobial therapy and omeprazole are prescribed when H. pylori is present.

105 trointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13;

106 anaphylaxis was blunted in mice treated with omeprazole as was allergen-induced mast cell expansion a

107 breakthrough with placebo at bedtime; 7 with omeprazole at bedtime (P = NS); 4 with ranitidine, 150 m

108 Additional omeprazole at bedtime reduced the percentage of time wit

109 We compared the effect of a third dose of omeprazole at bedtime with that of a dose of ranitidine

110 [- 0.0615, - 0.0506], p value < 0.001), and omeprazole (ATE = - 0.0201 [- 0.0299, - 0.0103], p value

111 A series of omeprazole-based analogues was synthesized and assessed

112 Mice were injected with either IL-1beta or omeprazole before measuring Shh mRNA expression and acid

113 lyacrylamide gel electrophoresis showed that omeprazole bound covalently to one of the two cysteines

114 vascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically

115 Administration of the proton pump inhibitor omeprazole can reduce both esophageal mast cell and eosi

116 etronidazole, and tetracycline combined with omeprazole can reduce recurrence rates.

117 Acid blockers, such as omeprazole, can heal peptic ulcers in approximately 80%

118 Regimen 1, omeprazole + clarithromycin (O/C), was supported by two

119 vergrowth between patients given PHOPDT plus omeprazole compared with only omeprazole.

120 from randomized controlled trials evaluating omeprazole compared with placebo showed no difference in

121 surgery and 6 months of once- or twice-daily omeprazole (controls, n = 42).

122 At 10 years, LNF and omeprazole costs were similar.

123 in the canine model, physiological doses of omeprazole decrease CSF production by about 26%.

124 Prior mechanistic studies reported that omeprazole decreases the platelet inhibitory effects of

125 cokinetic and pharmacodynamic responses with omeprazole demonstrated assay sensitivity.

126 ice, were almost completely restored through omeprazole, demonstrating that urease production in L. r

127 jects taking a hydrogen pump blocking agent (omeprazole) develop bacterial overgrowth of the small in

128 metabolizing enzymes (caffeine, tolbutamide, omeprazole, dextromethorphan, and oral and intravenous m

129 y, since Sch 28080 which is more potent than omeprazole did not significantly affect CSF production.

130 AIM: To compare the efficacy and safety of omeprazole-domperidone combination vs omeprazole monothe

131 Omeprazole-domperidone combination was more effective th

132 diet for 35 d were randomly assigned to take omeprazole during the first period of study or starting

133 Hence, the local release of omeprazole enables its action as a phospholipid-like dru

134 t patients take no more than low-dose (20-mg omeprazole equivalents) PPI daily.

135 ization for GIB (HR, 1.07 per 320 mg-months [omeprazole equivalents]; 95% CI, 1.06-1.08; P < .001).

136 s conducted using data from SPCs for 5 PPIs (omeprazole, esomeprazole, lansoprazole, pantoprazole, an

137 H2RAs (famotidine) or PPIs (pantoprazole, omeprazole, esomeprazole, or lansoprazole).

138 Murine and human mast cells treated with omeprazole exhibited diminished degranulation and releas

139 in which hypergastrinemia was induced using omeprazole, following gamma-radiation, 5-fluorouracil, a

140 and PAM were unchanged after treatment with omeprazole for 5 days, whereas gastrin, PC1/3 and PC2 mR

141 ), was increased 3-fold after treatment with omeprazole for either 1 or 5 days.

142 , incubated in vitro, from rats treated with omeprazole for up to 5 days.

143 uded in the Gaviscon(R) group and 121 in the omeprazole group for the per protocol non-inferiority an

144 days by D7 was significantly greater in the omeprazole group: 3.7 +/- 2.3 days vs. 3.1 +/- 2.1 (p =

145 centration of clopidogrel active metabolite (omeprazole > esomeprazole > lansoprazole > dexlansoprazo

146 Omeprazole had no significant inhibitory effect on the a

147 Omeprazole has shown remarkable efficacy and safety in t

148 tagastrin (pH 3.5 +/- 0.2) and eliminated by omeprazole, implicating parietal cell H,K-ATPase as the

149 Nausea resolved after treatment with omeprazole in 7 patients, after treatment with cisapride

150 Gaviscon(R) was non-inferior to omeprazole in achieving a 24-h heartburn-free period in

151 nt literature discusses the use of high-dose omeprazole in diagnosing and treating chest pain associa

152 ease in intraluminal pH that was reversed by omeprazole in fundic organoids and indicated functional

153 a more potent inhibitor of K+,H+-ATPase than omeprazole, in canine cerebrospinal fluid (CSF) producti

154 cid secretion by proton pump inhibitors like omeprazole increases the synthesis and secretion of the

155 We report here how omeprazole influences the conversion of the gastrin prec

156 inhibited ATPase activity and SCH 28080- and omeprazole-inhibited 86Rb uptake.

157 Only removal of Cys822 blocked omeprazole inhibition of 86Rb transport.

158 d omeprazole suspension (containing 40 mg of omeprazole) initially, followed by a second 20-mL dose 6

159 Omeprazole intercalates among DPPC molecules, promoting

160 Omeprazole is a proton pump inhibitor used in the treatm

161 The proton pump inhibitor omeprazole is administered to dogs with gastroduodenal u

162 d indications for use of both drugs, we find omeprazole is often administered outside dosing recommen

163 In people, omeprazole is overprescribed in hospitals, increasing th

164 Omeprazole is usually administered under an enteric coat

165 Thermolysin digestion of the isolated omeprazole-labeled fifth and sixth transmembrane pair sh

166 ality-adjusted life years per patient), with omeprazole less expensive than LNF ($6053 vs. $9482 per

167 Omeprazole may predispose to small intestinal bacterial

168 gnificantly lower with rabeprazole than with omeprazole (median 1 [1,2] vs. 2 [1-3], p = 0.04).

169 Interestingly, decreasing the pH(c) by omeprazole-mediated inhibition of Pma1 led to Snf1 activ

170 performed by human CYP2C19, the major human omeprazole-metabolizing P450 enzyme.

171 H. pylori eradication therapy using omeprazole, metronidazole, and clarithromycin was admini

172 ety of omeprazole-domperidone combination vs omeprazole monotherapy in gastroesophageal reflux diseas

173 ntoprazole (n = 9), rabeprazole (n = 2), and omeprazole (n = 1).

174 utilized for the sensitive determination of omeprazole (OME).

175 g CYP102A1 for stereoselective metabolism of omeprazole (OMP), a proton pump inhibitor, starting from

176 stasis, we sought to evaluate the effects of omeprazole on mast cell functions including development,

177 me ranitidine is more effective than bedtime omeprazole on residual nocturnal acid secretion in patie

178 The effects of omeprazole on these responses were investigated as was i

179 ce a day for the following 3 weeks and 20 mg omeprazole once daily for a further 4 weeks.

180 6 of whom were treated for 8 days with 20 mg omeprazole or 20 mg rabeprazole in a 2-way crossover fas

181 iple Doses of Dexiansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and P

182 ical therapy or requiring daily therapy with omeprazole or high-dose H2 antagonists.

183 on of ATPase following inhibition in vivo by omeprazole or its enantiomers was seen with dithiothreit

184 fen), adding a proton pump inhibitor such as omeprazole or lansoprazole, and eradicating H pylori wit

185 locking with proton pump inhibitors, such as omeprazole or lansoprazole, is the primary treatment.

186 527,364 lansoprazole initiators and 923,500 omeprazole or pantoprazole initiators.

187 ears; 95% confidence interval 8.1-12.4) than omeprazole or pantoprazole users (n = 193; 15.3 cases pe

188 rs have a lower incidence of TB disease than omeprazole or pantoprazole users.

189 ceive clopidogrel in combination with either omeprazole or placebo, in addition to aspirin.

190 t decrease (reduced-function CYP2C19 allele; omeprazole) or increase (cigarette smoking) the metaboli

191 udied a cohort of new users of lansoprazole, omeprazole, or pantoprazole from the United Kingdom Clin

192 Twenty one Wistar rats were given omeprazole orally or intravenously for 30 days, and caer

193 , gabapentin, atorvastatin, fluticasone, and omeprazole) originally intended for other indications wi

194 gnificantly lower with rabeprazole than with omeprazole (p < 0.0001).

195 ity of pain relief was slightly in favour of omeprazole (p = 0.049).

196 s for Gaviscon(R) and 2.0 (+/- 2.3) days for omeprazole (p = 0.93); mean intergroup difference was 0.

197 Prescription of omeprazole, pantoprazole, lansoprazole, esomeprazole, or

198 n fundoplication), active medical treatment (omeprazole plus baclofen, with desipramine added dependi

199 on symptoms), or control medical treatment (omeprazole plus placebo).

200 rough nanoindentation studies on a series of omeprazole polymorphs, in which the proportions of the 5

201 During treatment with omeprazole, postprandial reflux becomes predominantly no

202 cessed by the cationic sulfenamide formed by omeprazole, presumably the turn between M5 and M6.

203 Subjects were given omeprazole, rabeprazole or placebo in a randomized order

204 th either saline or an antisecretory dose of omeprazole, ranitidine, or cimetidine, were intragastric

205 In addition, omeprazole reduced tyrosinase protein abundance in the p

206 ings are consistent with the hypothesis that omeprazole reduces melanogenesis by inhibiting ATP7A and

207 imens 1 and 2; n = 6) or in combination with omeprazole (regimen 3; n = 4), or bismuth subsalicylate

208 ked immunosorbent assay after treatment with omeprazole, SCH 28080 (potassium-competitive acid blocke

209 of PPIs and randomized controlled trials of omeprazole seem to provide conflicting results for the e

210 able to activate acid secretion through the omeprazole-sensitive H+,K+ -ATPase even in the absence o

211 When locally absorbed, omeprazole shows a higher efficacy and a cytoprotective

212 Strikingly, the proton-pump inhibitor omeprazole similarly altered the microbiome and delayed

213 Patients received 20 mL of simplified omeprazole suspension (containing 40 mg of omeprazole) i

214 Patients were randomized to treatment with omeprazole suspension (two 40-mg doses on day 1, via oro

215 in the per-protocol population was 4.5% with omeprazole suspension and 6.8% with cimetidine, meeting

216 e, phase 3, double-blind trial with parallel omeprazole suspension and cimetidine treatment groups.

217 In the omeprazole suspension group, median gastric pH was >4 on

218 Immediate-release omeprazole suspension is effective in preventing upper g

219 Simplified omeprazole suspension prevented clinically significant u

220 astric pH was > or =6 on all trial days with omeprazole suspension treatment and on 50% of days with

221 Simplified omeprazole suspension was administered through a nasogas

222 eting the criteria for the noninferiority of omeprazole suspension.

223 er gastrointestinal bleeding after receiving omeprazole suspension.

224 Our findings suggest that omeprazole targets pathways important for the differenti

225 is study was to evaluate the efficacy of the omeprazole test (OT) in diagnosing gastroesophageal refl

226 ridyl-methylsulfinyl-benzimidazoles, such as omeprazole, that convert to thiophilic probes of luminal

227 ally used drugs including the antiulcer drug omeprazole, the anxiolytic drug diazepam, the beta-block

228 Long-term omeprazole therapy in H. pylori-positive patients with Z

229 as started, and the lowest gastric pH during omeprazole therapy.

230 was poor (from 0.23 [95% CI, 0.21-0.25] for omeprazole to 0.27 [95% CI, 0.24-0.29] for pantoprazole

231 Omeprazole topically applied to the skin of UV-irradiate

232 e percent decreases in CSF production in the omeprazole treated group were 26 +/- 17 and 24 +/- 13 at

233 ) were invited to be randomly assigned to an omeprazole-treated (hypochlorhydric) group or a non-omep

234 ole-treated (hypochlorhydric) group or a non-omeprazole-treated group, but 6 subjects chose not to pa

235 nomas from the small and large intestines of omeprazole-treated mice were increased 35 and 29%, respe

236 ed within 240 min of the labelling period in omeprazole-treated samples, but secretion of labelled ga

237 episodes were detected before and 261 after omeprazole treatment (P > 0.05).

238 n the period when the diet was combined with omeprazole treatment (P > 0.05).

239 weeks in the controls to 10 weeks following omeprazole treatment (P < 0.00001, log-rank test).

240 line (P < 0.05); however, the combination of omeprazole treatment and the phylloquinone-restricted di

241 Omeprazole treatment increased the proportion of EndoH s

242 recovery of acid secretion in rats following omeprazole treatment is approximately 15 hours, whereas

243 ression, similar to the levels obtained with omeprazole treatment of wild-type mice.

244 In contrast, omeprazole treatment resulted in mild progression of gas

245 icted diet or during the period of diet plus omeprazole treatment.

246 relief of their heartburn during the 2-week omeprazole trial, 70 did not complete trial procedures,

247 g tinidazole twice a day for 1 week or 20 mg omeprazole twice a day and identical placebos.

248 egative patients were given open label 20 mg omeprazole twice a day for 1 week.

249 All patients received 20 mg omeprazole twice a day for the following 3 weeks and 20

250 ned (2:1) to receive PHOPDT (n=138) or 20 mg omeprazole twice daily (n=70).

251 r PPI-refractory heartburn received 20 mg of omeprazole twice daily for 2 weeks, and those with persi

252 cturnal acid secretion in patients receiving omeprazole twice daily is most likely histamine related.

253 with 150 mg and 6% with 300 mg (P <0.01 vs. omeprazole twice daily plus bedtime).

254 <4 from 48% to 31% (P < 0.005) compared with omeprazole twice daily with placebo at bedtime.

255 ithout medication, session 2 after 7 days of omeprazole twice daily.

256 cturnal acid secretion in patients receiving omeprazole twice daily.

257 cturnal acid secretion in patients receiving omeprazole twice daily.

258 They then took PPIs for 4 weeks (40 mg omeprazole, twice daily) and fecal samples were collecte

259 o 5 days with the H(+)-K(+)-ATPase inhibitor omeprazole, VMAT2, histidine decarboxylase and chromogra

260 en lansoprazole vs. ranitidine (p< .01), and omeprazole vs. ranitidine (p< .05), and no significant d

261 s 6.8, and the mean lowest pH after starting omeprazole was 5.6.

262 was 7.1, the mean gastric pH after starting omeprazole was 6.8, and the mean lowest pH after startin

263 parietal cell Shh expression by IL-1beta and omeprazole was additive.

264 Omeprazole was discontinued at 8 weeks and patients were

265 easures were gastric pH measured 4 hrs after omeprazole was first administered, mean gastric pH after

266 ested, and ion enhancement of about 500% for omeprazole was observed in one lot but not in the other.

267 as first administered, mean gastric pH after omeprazole was started, and the lowest gastric pH during

268 response to a single dose of rabeprazole and omeprazole was strong and not significantly different be

269 al of 518 potentially interacting drugs with omeprazole were reported, 455 for esomeprazole, 433 for

270 and 1 observational) assessed the effect of omeprazole when added to DAPT; the other 30 (observation

271 he H2-antagonist failed, 52% would change to omeprazole, whereas 67% would change to an H2-antagonist

272 tion of S-mephenytoin and 5-hydroxylation of omeprazole, while the structurally homologous P450 2C9 h

273 (n=142, H. pylori eradication treatment), or omeprazole with placebo antibiotics (n=143, controls) fo